Elicio Therapeutics
ELTX
47 hedge funds and large institutions have $13.8M invested in Elicio Therapeutics in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 19 reducing their positions, and 12 closing their positions.
1.62% less ownership
Funds ownership: 23.42% → 21.8% (-1.6%)
11% less funds holding
Funds holding: 53 → 47 (-6)
32% less capital invested
Capital invested by funds: $20.3M → $13.8M (-$6.48M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
63% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$764K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$282K |
| 3 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
+$90.3K |
| 4 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
+$75.6K |
| 5 |
Renaissance Technologies
New York
|
+$73.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$718K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$606K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$212K |
| 4 |
Two Sigma Investments
New York
|
-$188K |
| 5 |
Millennium Management
New York
|
-$182K |
ELTX Hedge Fund Activity: Q1 2022 in Review
47 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q1 2022, worth a combined $13.8M — down 32% from $20.3M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ELTX and 6 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 7 added.
The largest buyer was CM Management, adding an estimated $764K. The largest seller was Russell Investments Group, exiting entirely with an estimated $718K sold.
- 47 institutional investors held Elicio Therapeutics (ELTX) as of Q1 2022, down from 53 in Q4 2021.
- Funds reported $13.8M of Elicio Therapeutics stock for Q1 2022, down 32% quarter-over-quarter.
- 6 funds opened new Elicio Therapeutics positions in Q1 2022 and 12 closed out, a net change of -6 holders.
- The largest Elicio Therapeutics buyer in Q1 2022 was CM Management, an estimated $764K added.
- The largest Elicio Therapeutics seller in Q1 2022 was Russell Investments Group, an estimated $718K sold.
Based on aggregated 13F filings for Q1 2022.